Hypermarcas (OTCMKTS:HYPMY) Shares Cross Below 50 Day Moving Average - What's Next?

Key Points

• Hypermarcas shares fell below their 50-day moving average of $4.76, reaching a low of $4.22 before closing at $4.35.
• Despite the dip, Scotiabank upgraded Hypermarcas to a "strong-buy" rating on July 17th.
• The company announced a dividend of $0.0345, with a substantial dividend yield of 281.0%, payable on January 8th to investors on record from July 1st.

Hypermarcas (OTCMKTS:HYPMY - Get Free Report)'s share price passed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $4.76 and traded as low as $4.22. Hypermarcas shares last traded at $4.35, with a volume of 7,152 shares.

Analyst Upgrades and Downgrades

Separately, Scotiabank upgraded shares of Hypermarcas to a "strong-buy" rating in a report on Thursday, July 17th.

Hypermarcas Trading Down 1.1%

The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.80 and a current ratio of 1.26. The company's fifty day simple moving average is $4.76 and its 200-day simple moving average is $3.97. The company has a market capitalization of $2.76 billion, a P/E ratio of 20.72 and a beta of 0.77.

Hypermarcas (OTCMKTS:HYPMY - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported $0.12 EPS for the quarter. Hypermarcas had a net margin of 11.28% and a return on equity of 6.19%.

Hypermarcas Dividend Announcement

The business also recently disclosed a dividend, which will be paid on Friday, January 8th. Investors of record on Tuesday, July 1st will be given a $0.0345 dividend. This represents a dividend yield of 281.0%. The ex-dividend date of this dividend is Monday, June 30th. Hypermarcas's dividend payout ratio (DPR) is presently 50.00%.

About Hypermarcas

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.